Decreased CCKB receptor binding in rat amygdala in animals demonstrating greater anxiety-like behavior

Psychopharmacology

Volumn 164, Issue 2, 2002, Pages 193-199

  Wunderlich, Glen R ^a   Raymond, Roger ^b   DeSousa, Norberto J ^a   Nobrega, José N ^a,b   Vaccarino, Franco J ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

Author keywords

Anxiety; Autoradiography; Cholecystokinin; Individual differences; Nucleus accumbens; Plus maze

Indexed keywords

CHOLECYSTOKININ RECEPTOR; IODINE 125; LIGAND; TRITIUM;

AMYGDALOID NUCLEUS; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANXIETY; ARTICLE; BRAIN SLICE; CONTROLLED STUDY; FEAR; INCUBATION TIME; ISOTOPE LABELING; MALE; MAZE TEST; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR BINDING;

ACOUSTIC STIMULATION; AMYGDALA; ANALYSIS OF VARIANCE; ANIMALS; ANXIETY; AUTORADIOGRAPHY; BEHAVIOR, ANIMAL; CHOLECYSTOKININ; CONDITIONING, CLASSICAL; FEAR; MALE; MAZE LEARNING; NUCLEUS ACCUMBENS; RATS; RATS, WISTAR; RECEPTORS, CHOLECYSTOKININ; STARTLE REACTION;

EID: 0036908347     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00213-002-1181-4     Document Type: Article

References (59)

1. Adamec RE (1991) Acute and lasting effects of FG-7142 on defensive and approach-attack behavior in cats: Implications for models of anxiety. J Psychopharmacol 5:29-55
2. Adamec RE, Shallow T, Budgell J (1997) Blockade of CCK(B) but not CCK(A) receptors before and after the stress of predator exposure prevents lasting increases in anxiety-like behavior: Implications for anxiety associated with posttraumatic stress disorder. Behav Neurosci 11:435-449
3. Beinfeld MC, Meyer DK, Eskay RL, Jensen RT, Brownstein MJ (1981) The distribution of cholecystokinin immunoreactivity in the central nervous system of the rat as determined by radioimmunoassay. Brain Res 212:51-57
4. Belcheva L, Belcheva S, Petkov W, Petkov VD (1994) Asymmetry in behavioral responses to cholecystokinin microinjected into rat nucleus accumbens and amygdala. Neuropharmacology 33:995-1002
5. Bitsios P, Philpott A, Langley RW, Bradshaw CM, Szabadi E (1999) Comparison of the effects of diazepam on the fear-potentiated startle reflex and the fear-inhibited light reflex in man. J Psychopharmacol 13:226-234
6. Bradwejn J, Koszycki D, Meterissian G (1990) Cholecystokinin-tetrapeptide induces panic attacks in patients with panic disorder. Can J Psychiatry 35:83-85
7. Brown JS, Kalish HI, Farber IE (1951) Conditioned fear as revealed by magnitude of startle response to an auditory stimulus. J Exp Psychol 41:317-328
8. Crawley JN, Corwin RL (1994) Biological actions of cholecystokinin. Peptides 15:731-755
9. Dauge V, Dor A, Feger J, Roques BP (1989) The behavioral effects of CCK8 injected into the medial nucleus accumbens are dependent on the motivational state of the rat. Eur J Pharmacol 163:25-32
10. Dauge V, Bohme GA, Crawley JN, Durieux C, Stutzmann JM, Feger J, Blanchard JC, Roques BP (1990) Investigation of behavioral and electrophysiological responses induced by selective stimulation of CCKB receptors by using a new highly potent CCK analog, BC 264. Synapse 6:73-80
11. Davis M (1979) Diazepam and flurazepam: Effects on conditioned fear as measured with the potentiated startle paradigm. Psychopharmacology 62:1-7
12. Davis M (1992) The role of the amygdala in fear and anxiety. Annu Rev Neurosci 15:353-375
13. Davis M, Falls WA, Campeau S, Kim M (1993) Fear-potentiated startle: A neural and pharmacological analysis. Behav Brain Res 58:175-198
14. de Montigny C (1989) Cholecystokinin tetrapeptide induces panic-like attacks in healthy volunteers. Preliminary findings. Arch Gen Psychiatry 46:511-517
15. Derrien M, McCort-Tranchepain I, Ducos B, Roques BP, Durieux C (1994) Heterogeneity of CCK-B receptors involved in animal models of anxiety. Pharmacol Biochem Behav 49:133-141
16. 3H] CCK4 binding sites in mouse and rat brain. Neuropeptides 12:141-148
17. Fekete M, Lengyel A, Hegedus B, Penke B, Zarandy M, Toth GK, Telegdy G (1984) Further analysis of the effects of cholecystokinin octapeptides on avoidance behavior in rats. Eur J Pharmacol 98:79-91
18. Fendt M, Koch M, Kungel M, Schnitzler HU (1995) Cholecystokinin enhances the acoustic startle response in rats. Neuroreport 6:2081-2084
19. Frankland PW, Josselyn SA, Bradwejn J, Vaccarino FJ, Yeomans JS (1996) Intracerebroventricular infusion of the CCKB receptor agonist pentagastrin potentiates acoustic startle. Brain Res 733:129-132
20. B receptors potentiates the acoustic startle response in the rat. J Neurosci 17:1838-1847
21. 3H]pentagastrin. Peptides 4:755-762
22. Gaudreau P, St-Pierre S, Pert C, Quirion R (1985) Cholecystokinin receptors in mammalian brain: A comparative characterization and visualization. Ann NY Acad Sci 448:198-219
23. Griebel G (1999) Is there a future for neuropeptide receptor ligands in the treatment of anxiety disorders? Pharmacol Ther 82:1-61
24. Griebel G, Perrault G, Sanger DJ (1997) CCK receptor antagonists in animal models of anxiety: Comparison between exploration tests, conflict procedures and a model based on defensive behaviours. Behav Pharmacol 8:549-560
25. Grillon C, Ameli R, Goddard A, Woods SW, Davis M (1994) Baseline and fear-potentiated startle in panic disorder patients. Biol Psychiatry 35:431-439
26. Guscott MR, Cook GP, Bristow LJ (2000) Contextual fear conditioning and baseline startle responses in the rat fear-potentiated startle test: A comparison of benzodiazepine/gamma-aminobutyric acid-A receptor agonists. Behav Pharmacol 2000 11:495-504
27. Harro J, Vasar E, Bradwejn J (1993) CCK in animal and human research on anxiety. Trends Pharmacol Sci 14:244-249
28. Higgins GA, Sills TL, Tomkins DM, Sellers EM, Vaccarino FJ (1994) Evidence for the contribution of CCKB receptor mechanisms to individual differences in amphetamine-induced locomotion. Pharmacol Biochem Behav 48:1019-1024
29. Hill DR, Campbell NJ, Shaw TM, Woodruff GN (1987) Autoradiographic localization and biochemical characterization of peripheral type CCK receptors in rat CNS using highly selective nonpeptide CCK antagonists. J Neurosci 7:2967-2976
30. Honda T, Wada F, Battey JF, Wank SA (1993) Differential gene expression of CCK-A and CCK-B receptors in the rat brain. Mol Cell Neurosci 4:143-154
31. Hughes J, Boden P, Costall B, Domeney A, Kelly E, Horwell DC, Hunter JC, Pinnock RD, Woodruff GN (1990) Development of a class of selective cholecystokinin type B receptor antagonists having potent anxiolytic activity. Proc Natl Acad Sci USA 87:6728-6732
32. Innis RB, Snyder SH (1980) Distinct cholecystokinin receptors in brain and pancreas. Proc Natl Acad Sci USA 77:6917-6921
33. Ivy AC, Oldberg E (1928) Hormone mechanism for gall-bladder contraction and evacuation. Am J Physiol 86:599-613
34. Josselyn SA, Frankland PW, Petrisano S, Bush DE, Yeomans JS, Vaccarino FJ (1995) The CCKB antagonist, L-365,260, attenuates fear-potentiated startle. Peptides 16:1313-1315
35. Kehne JH, Cassella JV, Davis M (1988) Anxiolytic effects of buspirone and gepirone in the fear-potentiated startle paradigm. Psychopharmacology 94:8-13
36. Koks S, Soosaar A, Voikar V, Volke V, Ustav M, Mannisto PT, Bourin M, Vasar E (1998) Opioid antagonist naloxone potentiates anxiogenic-like action of cholecystokinin agonists in elevated plus-maze. Neuropeptides 32:235-240
37. Koks S, Soosaar A, Voikar V, Bourin M, Vasar E (1999) BOC-CCK-4, CCK(B) receptor agonist, antagonizes anxiolytic-like action of morphine in elevated plus-maze. Neuropeptides 33:63-69
38. Lotti VJ, Chang RSL (1989) A new potent and selective non-peptide gastrin antagonist and brain cholecystokinin receptor (CCK-B) ligand: L-365,260. Eur J Pharmacol 162:273-280
39. Maeda H, Maki S, Uchimura H (1988) Facilitatory effects of caerulein on hypothalamic defensive attack in cats. Brain Res 459:351-355
40. Mannisto PT, Lang A, Harro J, Peuranen E, Bradwejn J, Vasar E (1994) Opposite effects mediated by CCKA and CCKB receptors in behavioural and hormonal studies in rats. Naunyn-Schmiedeberg's Arch Pharmacol 349:478-484
41. Noble F, Roques BP (1999) CCK-B receptor: Chemistry, molecular biology, biochemistry and pharmacology. Prog Neurobiol 58:349-379
42. Ohlsson B, Borg K, Mulder H, Rehfeld JF, Axelson J, Sundler F (2000) Continuous infusion of cholecystokinin leads to down-regulation of the cholecystokinin-A receptor in the rat pancreas. Scand J Gastroenterol 35:612-618
43. Pande AC, Greiner M, Adams JB, Lydiard RB, Pierce MW (1999) Placebo-controlled trial of the CCK-B antagonist, CI-988, in panic disorder. Biol Psychiatry 46:860-862
44. Patrick CJ, Berthot BD, Moore JD (1996) Diazepam blocks fear-potentiated startle in humans. J Abnorm Psychol 105:89-96
45. Paxinos G, Watson C (1986) The Rat Brain in Stereotaxic Coordinates, 2nd Edn. Academic Press, New York
46. Powell KR, Barrett JE (1991) Evaluation of the effects of PD 134308 (CI-988), a CCK-B antagonist, on the punished responding of squirrel monkeys. Neuropeptides 19:75-78
47. Raiteri M, Paudice P, Vallebuona F (1993) Release of cholecys-tokinin in the central nervous system. Neurochem Int 22:519-527
48. Rao RV, Hadac EM, Roettger BF, Miller LJ (1997) Cholecystokinin-induced desensitization, receptor phosphorylation, and internalization in the CHP212 neuroblastoma cell line. J Neurochem 68:2356-2362
49. Rataud J, Darche F, Piot O, Stutzmann JM, Bohme GA, Blan-chard JC (1991) "Anxiolytic" effect of CCK-antagonists on plus-maze behavior in mice. Brain Res 548:315-317
50. Rex A, Barth T, Voigt JP, Domeney AM, Fink H (1994) Effects of cholecystokinin tetrapeptide and sulfated cholecystokinin octapeptide in rat models of anxiety. Neurosci Lett 172:139-142
51. Shlik J, Zhou Y, Koszycki D, Vaccarino FJ, Bradwejn J (1999) Effects of CCK-4 infusion on the acoustic eye-blink startle and psychophysiological measures in healthy volunteers. J Psychopharmacol 13:385-390
52. Singh L, Field MJ, Hughes J, Menzies R, Oles RJ, Vass CA, Woodruff GN (1991a) The behavioural properties of CI-988, a selective cholecystokinin B receptor antagonist. Br J Pharmacol 104:239-245
53. Singh L, Lewis AS, Field MJ, Hughes J, Woodruff GN (1991b) Evidence for an involvement of the brain cholecystokinin B receptor in anxiety. Proc Natl Acad Sci USA 88:1130-1133
54. Tsutsumi T, Akiyoshi J, Isogawa K, Kohno Y, Hikichi T, Nagayama H (1999) Suppression of conditioned fear by administration of CCKB receptor antagonist PD135158. Neuropeptides 33:483-486
55. Vaccarino FJ, Arifuzzaman AI, Sabijan SM, Wunderlich GR, DeSousa NJ, Bush DEA, Bradwejn J (1997) CCK-B receptor activation and anxiogenic behavior: A neuroanatomical analysis. Soc Neurosci Abstr 23:630.8
56. Vanderhaeghen JJ, Signeau JC, Gepts W (1975) New peptide in the vertebrate CNS reacting with antigastrin antibodies. Nature 257:604-605
57. Walker DL, Davis M (2002) The role of amygdala glutamate receptors in fear learning, fear-potentiated startle, and extinction. Pharmacol Biochem Behav 71:379-392
58. Wilson J, Watson WP, Little HJ (1998) CCK(B) antagonists protect against anxiety-related behaviour produced by ethanol withdrawal, measured using the elevated plus maze. Psychopharmacology 137:120-131
59. Zarbin MA, Innis RB, Wamsley JK, Snyder SH, Kuhar MJ (1983) Autoradiographic localization of cholecystokinin receptors in rodent brain. J Neurosci 3:877-906